Prellis is dedicated to building tissues to eliminate the organ transplant waitlist.

Our mission is to use novel tissue engineering technology to advance human health.

How is bioprinting different with Prellis technology?


Prellis uses patent-pending holographic laser projection technology to print at speeds fast enough to create entire organs while maintaining the fine feature size necessary to mimic human physiology.

In manufacturing, speed and resolution are often coupled, for example; imagine building a house with grains of sand rather than bricks. Instead of scanning a laser beam, Prellis optical systems project up to 2.5M points of light per second. The light photo-cures compatible inks into the prescribed tissue design.





How is bioprinting different with Prellis technology?


Prellis uses patent-pending holographic laser projection technology to print at speeds fast enough to create entire organs while maintaining the fine feature size necessary to mimic human physiology.

In manufacturing, speed and resolution are often coupled, for example; imagine building a house with grains of sand rather than bricks. Instead of scanning a laser beam, Prellis optical systems project up to 2.5M points of light per second. The light photo-cures compatible inks into the prescribed tissue design.





What distinguishes Prellis from other tissue engineering companies?


By combining expertise in the Chemistry, Optical Engineering, Microfluidics, Cell Biology, and Software development spaces, Prellis has developed a full-stack process and platform for end-to-end tissue development starting with high-resolution 3D design engineering and ending with bioreactor-based tissue maturation.
Prellis is already answering questions that other tissue engineering endeavors have yet to answer around basic capillary flow network design and engineering for organ compatibility. Our process is an end-to-end approach that produces ultrafast tissue scaffolds.





Why is Prellis active in the therapeutics space?


On the way to bioprinting large organs for transplantation, Prellis has built and validated smaller test-tissues including human lymph nodes and human liver. Prellis-engineered human tissues are able to replicate in vivo human processes without needing to access a human patient. Using exclusively Prellis technology, we are able to provide the first human synthetic tissue for drug discovery and testing. Our synthetic human tissue provides consistent access to functional human biology outside of the human test subjects, so the possibilities for accelerating accurate drug discovery and testing are endless.





What differentiates the EXIS™ antibody discovery platform?


The EXIS™ (Externalized human Immune System) platform uses human Lymph Node Organoids (LNOs) to replicate the human immune system in vitro. When an LNO is ‘challenged’ with a vaccine-like cocktail, Prellis is able to obtain fully human, class-switched antibody libraries of up to 100,000 antigen-specific antibodies in as little as 20 days. Prellis has obtained low nanomolar to picomolar affinity antibody libraries against 14 targets and is currently moving several human antibodies into IND enabling studies.

Contact us
if you are interested in rapid antibody discovery.





What other applications does EXIS™ have?


EXIS™ (Externalized Human Immune System) goes beyond ultra-fast human antibody discovery. The EXIS™ platform allows for full access to full human immune system responses and is currently being developed for the following clinical development applications:

  • Vaccine testing and development
  • De novo cancer antigen discovery
  • Immune system modulation studies
  • Immunogenicity testing
Contact us if you are interested in immunogenicity testing or vaccine development studies.





How is Prellis fostering the future of tissue engineering?


We believe a fundamental shift in health and medicine will occur as a direct result of human tissue and organ availability. The beginnings of this movement can be seen in the adoption of three-dimensional organoids for therapeutic screening and research. Cells in three-dimensional organoids better replicate the behavior of cells in the human body and provide more accurate therapeutic screens. Utilizing three-dimensional cell culture to screen therapeutics has the potential to save billions of dollars in R&D costs.

As we move towards this shift in health and medicine Prellis recognizes the need to engage scientists and the cell biology community as a whole.

We engage the academic community by supporting a research partner program where we significantly discount access to our vascular tissue scaffolds.
In addition, we host monthly Tissue Engineering Journal Clubs that feature presentations of cutting edge research from top tissue engineering scientists from around the world.





prellis-white-icon-01.png
Building The 3D World Together
© Prellis Biologics 2021
All rights reserved.
  • Twitter
  • Instagram
  • LinkedIn